Monday, November 16, 2009

European Medicines Agency EMEA Recommends Orphan Drug Status for Elafin in the Treatment of Esophagus Carcinoma

Nov 16, 2009 - Proteo, Inc.and its wholly-owned subsidiary Proteo Biotech AG announced today:

The Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) has issued a recommendation granting orphan drug status to Proteo's drug candidate Elafin for the treatment of esophagus carcinoma.

The details can be read here.

No comments: